ERBB2 and breast cancer: In this study, we leveraged on a label-free GeLC-MS/MS technique to compare the membrane proteomes of two representative and regularly used epithelial BC cell lines, such as the HCC-1954 (HER2+) and the MDA-MB-231 (TNBC) to a breast benign control cell line, MCF-10A.